Page 8 - Mary Cushman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Early anticlotting therapy offers benefits for moderately ill patients with Covid-19 COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly in the lungs, and is believed to contribute to progression to severe disease and death. New trial results show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. The study, led by investigators at St. Michael s Hospital, a site of Unity Health Toronto, and the University of Vermont Larner College of Medicine, is available as a preprint on MedRxiv.

Michelle sholzbergMary cushmanEmily hendersonCoagulation laboratory at stHealth research centreDefence research development canadaUniversity of vermont larner college medicineUnity health torontoUniversity of torontoMichael hospital foundationMichael hospital of unity health torontoHead of division hematologyJoseph healthcare foundationVermont larner collegeLarner collegeCoagulation laboratory